Methylenedioxymethamphetamine decreases plasmalemmal and vesicular dopamine transport: Mechanisms and implications for neurotoxicity

Journal of Pharmacology and Experimental Therapeutics

Volumn 300, Issue 3, 2002, Pages 1093-1100

  Paul Hansen, J ^a   Riddle, Evan L ^a   Sandoval, Verónica ^a   Brown, Jeffrey M ^a   Gibb, James W ^a   Hanson, Glen R ^a   Fleckenstein, Annette E ^a  

^a UNIVERSITY OF UTAH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

3,4 METHYLENEDIOXYMETHAMPHETAMINE; 3BETA (4 FLUOROPHENYL) 2BETA TROPANECARBOXYLIC ACID METHYL ESTER; CARRIER PROTEIN; DOPAMINE TRANSPORTER; PROTEIN KINASE C; PROTEIN KINASE C INHIBITOR; UNCLASSIFIED DRUG; VESICULAR MONOAMINE TRANSPORTER 2;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CELL MEMBRANE; CELL VACUOLE; CONTROLLED STUDY; CORPUS STRIATUM; DOPAMINE UPTAKE; DRUG MECHANISM; DRUG MEGADOSE; HYPERTHERMIA; LIGAND BINDING; MALE; NEUROTOXICITY; NONHUMAN; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; RAT; SYNAPTOSOME;

ANIMALS; BIOLOGICAL TRANSPORT; BODY TEMPERATURE; CELL MEMBRANE; COCAINE; DOPAMINE; DOPAMINE PLASMA MEMBRANE TRANSPORT PROTEINS; DOPAMINE UPTAKE INHIBITORS; HALLUCINOGENS; KINETICS; MALE; MEMBRANE GLYCOPROTEINS; MEMBRANE TRANSPORT PROTEINS; METHAMPHETAMINE; N-METHYL-3,4-METHYLENEDIOXYAMPHETAMINE; NERVE TISSUE PROTEINS; NEUROPEPTIDES; NEUROTOXINS; RATS; RATS, SPRAGUE-DAWLEY; SYNAPTIC VESICLES; TETRABENAZINE; VESICULAR BIOGENIC AMINE TRANSPORT PROTEINS; VESICULAR MONOAMINE TRANSPORT PROTEINS;

EID: 0036182254     PISSN: 00223565     EISSN: None     Source Type: Journal    
DOI: 10.1124/jpet.300.3.1093     Document Type: Article

References (38)

1. Methamphetamine rapidly decreases vesicular dopamine uptake
2. Regulation of the vesicular monoamine transporter-2: A novel mechanism for cocaine and other psychostimulants
3. Influence of methamphetamine and neuroleptic drugs on tyrosine hydroxylase activity
4. Effects of LC mobile phase composition on retention times for biogenic amines, and their precursors and metabolites
5. Methamphetamine neurotoxicity involves vacuolation of endocytic organelles and dopamine-dependent intracellular oxidative stress
6. Striatal subregions are differentially vulnerable to the neurotoxic effects of methamphetamine
7. Methamphetamineinduced decrease in vesicular dopamine uptake: Role of dopamine and hyperthermia
8. Differential effects of stimulants on monoaminergic transporters: Pharmacological consequences and implications for neurotoxicity
9. Differential effects of psychostimulants and related agents on dopaminergic and serotonergic transporter function
10. Rapid and reversible effects of methamphetamine on dopamine transporters
11. Increased methamphetamine neurotoxicity in heterozygous vesicular monoamine transporter 2 knock-out mice
12. Differential regional effects of methamphetamine on the activities of tryptophan and tyrosine hydroxylase
13. The effects of methamphetamine on serotonin transporter activity: Role of dopamine and hyperthermia
14. Analysis of VMAT binding after methamphetamine or MPTP treatment: Disparity between homogenates and vesicle preparations
15. The long-term effects of multiple doses of methamphetamine on neostriatal tryptophan hydroxylase, tryosine hydroxylase, choline acetyltransferase and glutamate decarboxylase activities
16. 3,4-Methylenedioxymethamphetamine ("ecstasy") selectively destroys brain serotonin terminals in rhesus monkeys
17. Effects of 3,4-methylenedioxyamphetamine and 3,4-methylenedioxymethamphetamine isomers on central serotonergic, dopaminergic and nigral neurotensin systems of the rat
18. Isolation of coated vesicles, plain synaptic vesicles, and flocculent material from a crude synaptosome fraction of guinea pig whole brain
19. Protein kinase C inhibitors block amphetamine-mediated dopamine release in rat striatal slices
20. Adrenal and striatal tyrosine hydroxylase activity after methamphetamine
21. Influence of methamphetamine on nigral and striatal tyrosine hydroxylase activity and on striatal dopamine levels
22. Nature of methamphetamine-induced rapid and reversible changes in dopamine transporters
23. Dopamine quinone formation and protein modification associated with the striatal neurotoxicity of methamphetamine: Evidence against a role for extracellular dopamine
24. Protein measurement with the folin phenol reagent
25. 3-4-Methyl-enedioxymethamphetamine-induced acute changes in dopamine transporter function
26. Methamphetamine-induced rapid decrease in dopamine transporter function: Role of dopamine and hyperthermia
27. Dopamine transporters and neuronal injury
28. Short-term and long-term effects of methamphetamine on biogenic amine metabolism in extra-striatal dopaminergic nuclei
29. Vesicular monoamine transporter-2: Immunogold localization in striatal axons and terminals
30. Methamphetamine-induced rapid and reversible changes in dopamine transporter function: An in vitro model
31. Amphetamine-induced loss of human dopamine transporter activity: An internalization-dependent and cocaine-sensitive mechanism
32. Long-term methamphetamine induced changes in brain catecholamines in tolerant rhesus monkeys
33. 2,6-Diamino-N-([1-(1-oxotridecyl)-2-piperidinyl] methyl)hexanamide (NPC 15437): A novel inhibitor of protein kinase C interacting at the regulatory domain
34. 3H]dopamine from rat striatal synaptic vesicles: Comparison with d-amphetamine
35. 3H]dopamine uptake
36. Brain dopamine neurotoxicity in baboons treated with doses of methamphetamine comparable to those recreationally abused by humans: Evidence from [11C]WIN-35,428 positron emission tomography studies and direct in vitro determinations
37. Striatal dopamine nerve terminal markers in human, chronic methamphetamine users